Retatrutide Peptide
Powerful Triple GLP-1 / GIP / Glucagon Agonist
The most advanced triple-receptor incretin compound for metabolic research. ≥98% purity by HPLC. Third-party COA included with every order. Ships worldwide.
Retatrutide Peptide — Product Specifications
All VantyxLabs compounds are produced under controlled conditions and independently verified before shipment. Every batch of this triple-agonist compound is tested for purity, molecular identity, and endotoxin levels by an accredited third-party laboratory.
| Parameter | Value | Method |
|---|---|---|
| Appearance | White to off-white powder | Visual |
| Purity | ≥98% | HPLC |
| Molecular Weight | ~4,700 Da | Mass Spectrometry |
| Solubility | Soluble in sterile water | In vitro |
| Endotoxin Level | <1 EU/mg | LAL assay |
What Is Retatrutide Peptide? Complete Research Overview
Retatrutide (research designation LY3437943) is a next-generation incretin compound engineered to simultaneously activate three key metabolic receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This triple-agonist profile makes LY3437943 one of the most studied compounds in advanced metabolic research today — and the only synthetic peptide that targets all three receptor axes in a single molecule.
Unlike earlier single or dual receptor agonists, this synthetic compound engages the entire incretin system at once — making it an exceptionally useful tool for studying energy homeostasis, lipid metabolism, and glucose regulation in preclinical contexts. Researchers working on obesity biology, hepatic lipid clearance, and multi-axis incretin signaling increasingly choose LY3437943 for its unmatched receptor coverage.
Background & Discovery
LY3437943 was developed by Eli Lilly and Company as part of the next wave of incretin-based metabolic therapies. Preclinical and early-phase clinical research published between 2022 and 2024 demonstrated notable effects on body weight and metabolic markers in study subjects.
Structurally related to semaglutide and tirzepatide, this compound extends the receptor-targeting profile by adding glucagon receptor activity — a receptor known to regulate hepatic glucose output and energy expenditure that neither predecessor targets.
Why Researchers Choose This Compound
LY3437943 is of significant interest for researchers studying multi-receptor incretin pathways, adipose tissue metabolism, hepatic lipid clearance, and the interaction between GLP-1, GIP, and glucagon signaling in animal models.
Its unique triple-agonist design provides a tool to explore combined receptor effects that no dual or single agonist can replicate — giving researchers a genuinely new experimental axis to work with.
Mechanism of Action: How Retatrutide Activates 3 Receptors
Understanding the distinct roles of each receptor target is essential for designing research protocols with LY3437943. Here is a breakdown of each activation pathway:
GLP-1 Receptor (Glucagon-Like Peptide-1)
GLP-1 receptor agonism is the most well-characterized pathway in incretin research. GLP-1 is released from intestinal L-cells following nutrient intake. Activation in research models is associated with enhanced glucose-stimulated insulin secretion, reduced glucagon release, and delayed gastric emptying. This is the mechanism shared with semaglutide and liraglutide — the most established compounds in this class.
GIP Receptor (Glucose-Dependent Insulinotropic Polypeptide)
GIP is released from duodenal K-cells and potentiates insulin secretion in a glucose-dependent manner. GIP receptor co-activation alongside GLP-1 produces additive metabolic effects in research settings. Tirzepatide validated this dual-pathway approach — the triple-agonist design of LY3437943 extends it further by adding glucagon activity on top.
Glucagon Receptor
The glucagon receptor is expressed primarily in the liver and drives hepatic glucose production and fat oxidation. Co-activation alongside GLP-1 (which counteracts gluconeogenic effects) allows researchers to study energy expenditure and lipolytic effects of glucagon signaling cleanly — a key research frontier not accessible with dual agonists.
The combination of all three pathways in a single molecule makes this a uniquely powerful tool for studying multi-axis metabolic signaling that no predecessor compound can replicate.
Retatrutide vs Other Incretin Peptides: Research Comparison
The table below compares the receptor profile of LY3437943 against other commonly researched incretin compounds to clarify its unique positioning:
| Compound | GLP-1 | GIP | Glucagon | Research Focus |
|---|---|---|---|---|
| Retatrutide (LY3437943) | ✓ | ✓ | ✓ | Triple agonist metabolic research |
| Tirzepatide | ✓ | ✓ | — | Dual incretin / glucose regulation |
| Semaglutide | ✓ | — | — | GLP-1 pathway, appetite regulation |
| Survodutide | ✓ | — | ✓ | Dual GLP-1/Glucagon, NASH models |
| Cagrilintide | — | — | — | Amylin analog, satiety signaling |
Certificate of Analysis & Quality Assurance
Every batch sold by VantyxLabs is tested by an independent, accredited third-party laboratory before shipment. Our COA covers purity, molecular weight, and endotoxin levels — giving researchers complete confidence in compound identity and quality.
What Our COA Covers
Each Certificate of Analysis includes HPLC chromatogram results confirming purity ≥98%, mass spectrometry data confirming molecular identity, endotoxin testing (LAL assay), and physical appearance verification. All batch numbers are fully traceable.
Storage & Handling
Store sealed lyophilized powder at −20°C for up to 24 months. Once reconstituted in sterile water, refrigerate at 4°C and use within 30 days. Avoid freeze-thaw cycles. Handle in a clean laboratory environment.
Retatrutide Research Timeline: Key Studies & Publications
The development of retatrutide peptide has been documented through a growing body of peer-reviewed research. Understanding the research timeline helps investigators contextualize where LY3437943 stands in the broader incretin science landscape and what questions remain open for further study.
2021 — Preclinical Discovery Phase
Eli Lilly's research team published early preclinical data establishing the triple-agonist binding profile of LY3437943. Animal model studies demonstrated dose-dependent reductions in body weight and hepatic fat content, with a favorable safety profile that supported progression to Phase 1 human trials. The glucagon receptor component showed particular promise for liver fat clearance in diet-induced obesity models.
2022 — Phase 1 Clinical Research
Phase 1 trials established the pharmacokinetic profile of retatrutide in human subjects, confirming its once-weekly dosing potential due to an extended half-life. Researchers documented the compound's receptor binding characteristics and early tolerability data. This phase validated the preclinical triple-agonist mechanism in a human pharmacological context, providing key data for researchers working on incretin pathway modeling.
2023 — Phase 2 SURMOUNT-1 Results Published
The landmark Phase 2 trial results for retatrutide were published in the New England Journal of Medicine in 2023, representing a significant milestone for triple-agonist peptide research. The trial documented substantial effects on metabolic markers across multiple dose cohorts over a 24-week period, generating considerable scientific interest in the triple GLP-1/GIP/Glucagon receptor agonism model. The published data has since become a key reference for preclinical researchers designing animal studies with LY3437943.
2024–Present — Active Research Expansion
Following the Phase 2 publication, academic and independent research groups worldwide began investigating retatrutide's mechanisms in greater depth — particularly its glucagon receptor component and its effects on hepatic lipid metabolism, adipose tissue browning, and NASH pathology. This is currently one of the most actively published areas in metabolic peptide research, and demand for research-grade LY3437943 has grown substantially as a result.
For researchers wanting to review the primary literature, the Phase 2 results are publicly available via the New England Journal of Medicine and additional mechanistic studies are indexed on PubMed (NIH).
Retatrutide Peptide: Reconstitution & Research Handling Guide
Proper reconstitution and handling of lyophilized retatrutide peptide is essential to maintaining compound integrity during research. The following guidance applies to standard laboratory research protocols for this class of synthetic peptide.
Reconstitution Protocol
Lyophilized LY3437943 should be reconstituted using bacteriostatic water or sterile phosphate-buffered saline (PBS). Allow the vial to reach room temperature before opening. Add solvent slowly along the side of the vial — do not inject directly onto the powder. Gently swirl (do not vortex) until fully dissolved. A typical research reconstitution concentration is 1–2 mg/mL depending on the protocol requirements.
Once reconstituted, the solution should appear clear and colorless. Any cloudiness or particulate matter indicates potential degradation and the batch should not be used in research.
Storage After Reconstitution
Reconstituted retatrutide peptide solution should be stored at 4°C (refrigerator temperature) and used within 28–30 days for optimal stability. Aliquoting into single-use volumes before freezing at −20°C can help avoid repeated freeze-thaw cycles, which degrade peptide integrity over time.
For long-term storage of unused lyophilized stock, maintain at −20°C in a sealed, desiccated container away from light. Under these conditions, stability is maintained for up to 24 months from the date of manufacture as confirmed by our third-party COA testing.
| Step | Action | Notes |
|---|---|---|
| 1. Warm vial | Allow to reach room temperature | Prevents condensation on powder |
| 2. Add solvent | Bacteriostatic water or sterile PBS | Add slowly along vial wall |
| 3. Dissolve | Gently swirl — do not vortex | Full dissolution = clear solution |
| 4. Aliquot | Divide into research-use volumes | Minimizes freeze-thaw cycles |
| 5. Store | 4°C for active use; −20°C for stock | Use reconstituted within 30 days |
Who Orders Retatrutide Peptide from VantyxLabs?
VantyxLabs serves a global community of qualified researchers and investigators who require reliable access to research-grade incretin peptides. Understanding the primary research applications helps prospective customers confirm whether LY3437943 is the right compound for their specific investigative needs.
Academic & University Researchers
University-based research groups studying metabolic disease, obesity biology, and incretin signaling are among the primary users of retatrutide peptide. The compound's triple-receptor profile makes it an essential tool for researchers who need to model the full incretin axis in animal studies — particularly groups studying GLP-1/GIP/Glucagon interactions that cannot be replicated with commercially available single or dual agonists.
VantyxLabs provides COA documentation suitable for academic laboratory records, with full batch traceability for research compliance purposes.
Independent & Private Research Labs
Private research organizations and contract research organizations (CROs) conducting metabolic studies, NASH/MASH model work, and obesity research frequently require reliable international sources for novel incretin peptides. As US-based vendors often do not stock LY3437943, VantyxLabs serves as a primary supplier for international research teams needing consistent, high-purity access to this compound.
Bulk research quantities are available — contact us via WhatsApp to discuss larger order requirements and institutional pricing.
International Researchers Without Local Access
One of VantyxLabs' most important functions is serving researchers in countries where novel peptide compounds simply aren't available through local or regional suppliers. Retatrutide peptide is produced by a small number of specialized synthesis laboratories globally, and distribution channels outside North America are extremely limited. VantyxLabs ships to Europe, Asia, the Middle East, Southeast Asia, and beyond — giving international researchers the same access to cutting-edge compounds as their North American counterparts. See our worldwide shipping page for full destination details.
